Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 10c

August 9, 2021 4:49 PM EDT

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65).

GUIDANCE:

Rocket expects its balance in cash, cash equivalents and investments of $426.8 million as of June 30, 2021 to fund its operations into the second half of 2023, including the continued buildout and initiation of AAV cGMP manufacturing capabilities at our Cranbury, New Jersey R&D and manufacturing facility and continued development of our five clinical programs.

We are grateful to the FDA for its support and for working with us on our Danon program toward... More